ArticleArchives of toxicology2025
Chronic arsenic exposure and hsa-miR-186 overexpression causes transcriptome-wide differential alternative splicing contributing to skin carcinogenesis in human HaCaT cell line.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 6PPDQ Promotes Cutaneous Squamous Cell Carcinoma Growth with PI3K-Akt/MMP9 Activation: Evidence from Integrated Network Toxicology and Experimental Investigation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Environmental arsenic exposure causes skin cancer. Overexpression of hsa-miR-186 (mir-186) accelerated the malignant transformation of human keratinocytes by inorganic arsenic (iAs). Dysregulated alternative splicing is a key driver of carcinogenesis. iAs exposure disrupts alternative splicing. miR-186 is predicted to target several broad-spectrum splice regulators. The impact of miR-186 overexpression on differential alternative splicing alone and together in combination with iAs exposure and how that contributes to skin carcinogenesis has never been studied. We address this knowledge gap by investigating the transcriptome-wide differential alternative splicing events in preclinical HaCaT human keratinocyte clonal lines overexpressing miR-186 or scrambled control vectors concomitantly exposed to 0 or 100 nM iAs (up to 29 weeks). Differential alternative splicing events (FDR < 0.05 and IΔΨI ≥ 5%) and differentially expressed genes (p < 0.05) were identified by replicate multivariate analysis of transcript splicing (rMATS) and unpaired t test, respectively, on short-read RNA-seq data at 12- and 29-week time points. Functional impact of differential alternative splicing was assessed using Gene Ontology (GO) analysis on differentially spliced genes, as well as Ingenuity Pathway Analysis (IPA) on genes that were simultaneously differentially spliced and differentially expressed. Over 1500 alternative splicing events were detected in each pairwise comparison. miR-186 overexpression led to differential splicing of many splice regulators. Multiple cancer-related pathways were enriched and dysregulated in the miR-186 overexpressing clones with iAs exposure by GO and IPA analysis, respectively, explaining why the combination accelerates transformation. We show that dysregulated alternative splicing plays a key role in arsenic-induced cSCC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.